Pandemic Assistance Core

Goal & Research Areas

Perform initial in vitro screening of drug candidates for SARS-CoV-2

Determine EC50 and CC50 for the most promising candidates screened in Aim 1 against SARS-CoV-2 and other priority BSL3 pathogens

Perform in vivo testing of select antivirals to identify new therapeutic candidates

Define drug efficacy, toxicity, and mechanism of action in Air- Liquid-Interface(ALI) model and human adult lung organoids (ALOs)

Core Leader & Team

Catherine A. Blish

Catherine A. Blish

Learn More Learn More
Chien-Te (Kent) Tseng

Chien-Te (Kent) Tseng

Learn More Learn More
Timothy Sheahan

Timothy Sheahan

Learn More Learn More
Jeff Hogan

Jeff Hogan

Learn More Learn More
Claude Nagamine

Claude Nagamine

Learn More Learn More
Peter Jackson

Peter Jackson

Learn More Learn More
Jaishree Garhyan

Jaishree Garhyan

Learn More Learn More

Hot Topic

Jeffrey Glenn receives $69 million to start antiviral drug-discovery center at Stanford

Jeffrey Glenn receives $69 million to start antiviral drug-discovery center at Stanford

The National Institute for Allergy and Infectious Diseases has awarded Jeffrey Glenn, MD, PhD, professor of hepatology and gastroenterology and of microbiology and immunology, $69 million...

Read More Learn More
Single drug injection wards off COVID-19 hospitalizations, in Stanford Medicine-led trial

Single drug injection wards off COVID-19 hospitalizations, in Stanford Medicine-led trial

A single dose of lambda-interferon reduced hospitalization among COVID-19 outpatients in a late-stage study spearheaded by a Stanford Medicine virologist.

Read More Learn More
Antiviral Program for Pandemics

Antiviral Program for Pandemics

The Antiviral Program for Pandemics (APP) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.

Read More Learn More